Achelios Therapeutics
Achelios Therapeutics, a US-based company, innovates superior tissue-penetrating NSAID products using proprietary technology.
Founded
2012Achelios Therapeutics, a US-based company, innovates superior tissue-penetrating NSAID products using proprietary technology.
Achelios Therapeutics, founded in Chapel Hill, United States, is dedicated to developing advanced NSAID products with superior tissue penetration using their proprietary ACHETOGEL™ delivery technology. Their core mission is to provide effective topical treatments for pain and inflammation, targeting conditions such as temporomandibular joint disorder (TMJD), menstrual migraines, and chronic inflammatory joint pain. Their lead product, TOPOFEN™, utilizes the NSAID ketoprofen and has demonstrated promising results in pre-clinical and early-stage clinical studies.
Achelios Therapeutics has garnered attention for its innovative approach to pain management, attracting notable investors and industry experts. The company's achievements include securing patents for their unique delivery technology and advancing TOPOFEN™ through critical stages of development. Their impact lies in offering non-invasive, effective alternatives to traditional pain relief methods, potentially improving the quality of life for individuals suffering from chronic pain conditions.
Companies similar to Achelios Therapeutics include Akelos, Exodos Life Sciences, Isosceles Pharmaceuticals and Concentric Analgesics.
Achelios Therapeutics was founded in 2012.
Achelios Therapeutics' headquarters is located in Chapel Hill, NC, US.
Achelios Therapeutics' most recent funding round was for $350k (USD) in April 2016.
As of Apr 19, 2016, Achelios Therapeutics has disclosed funding of $3.5M (USD). Undisclosed round amounts are excluded.
Achelios Therapeutics has 5 employees as of Feb 5, 2024.
Concentric Analgesics
